Literature DB >> 21557274

Dedifferentiation of prostate smooth muscle cells in response to bacterial LPS.

Carolina Leimgruber1, Amado A Quintar, Liliana D V Sosa, Luciana N García, Mauricio Figueredo, Cristina A Maldonado.   

Abstract

BACKGROUND: Prostate smooth muscle cells (SMCs) are strongly involved in the development and progression of benign prostatic hyperplasia and prostate cancer. However, their participation in prostatitis has not been completely elucidated. Thus, we aimed to characterize the response of normal SMC to bacterial lipopolysaccharide (LPS).
METHODS: Primary prostate SMCs from normal rats were stimulated with LPS (0.1, 1, or 10 µg/ml) for 24 or 48 hr. The phenotype was evaluated by electron microscopy, immunofluorescence, and Western blot of SMCα-actin (ACTA2), calponin, vimentin, and tenascin-C, while the innate immune response was assessed by immunodetection of TLR4, CD14, and nuclear NF-κB. The secretion of TNFα and IL6 was determined using ELISA.
RESULTS: Bacterial LPS induces SMCs to develop a secretory phenotype including dilated rough endoplasmic reticulum cisternae with well-developed Golgi complexes. Furthermore, SMCs displayed a decrease in ACTA2 and calponin, and an increase in vimentin levels after LPS challenge. The co-expression of ACTA2 and vimentin, together with the induction of tenascin-C expression indicate that a myofibroblastic-like phenotype was induced by the endotoxin. Moreover, LPS elicited a TLR4 increase, with a peak in NF-κB activation occurring after 10 min of treatment. Finally, LPS stimulated the secretion of IL6 and TNFα.
CONCLUSIONS: Prostate SMCs are capable of responding to LPS in vitro by dedifferentiating from a contractile to a miofibroblastic-like phenotype and secreting cytokines, with the TLR4 signaling pathway being involved in this response. In this way, prostate SMCs may contribute to the pathophysiology of inflammatory diseases by modifying the epithelial-stromal interactions.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21557274     DOI: 10.1002/pros.21322

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  6 in total

1.  Persistent inflammation leads to proliferative neoplasia and loss of smooth muscle cells in a prostate tumor model.

Authors:  Andreas Birbach; David Eisenbarth; Nicolas Kozakowski; Eva Ladenhauf; Marc Schmidt-Supprian; Johannes A Schmid
Journal:  Neoplasia       Date:  2011-08       Impact factor: 5.715

2.  Influence of 4% icodextrin solution on peritoneal tissue response and adhesion formation.

Authors:  Christian D Klink; Patrick Schickhaus; Marcel Binnebösel; Stefan Jockenhoevel; Rafael Rosch; Rene Tolba; Ulf P Neumann; Uwe Klinge
Journal:  BMC Surg       Date:  2013-09-10       Impact factor: 2.102

3.  Testosterone suppresses uropathogenic Escherichia coli invasion and colonization within prostate cells and inhibits inflammatory responses through JAK/STAT-1 signaling pathway.

Authors:  Chen-Hsun Ho; Chia-Kwung Fan; Hong-Jeng Yu; Chia-Chang Wu; Kuan-Chou Chen; Shih-Ping Liu; Po-Ching Cheng
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

4.  Nonalcoholic Fatty Liver Disease Is Associated with Benign Prostate Hyperplasia.

Authors:  Goh Eun Chung; Jeong Yoon Yim; Donghee Kim; Min Sun Kwak; Jong In Yang; Boram Park; Seong Joon An; Joo Sung Kim
Journal:  J Korean Med Sci       Date:  2020-06-08       Impact factor: 2.153

5.  Integrins and Epithelial-Mesenchymal Cooperation in the Tumor Microenvironment of Muscle-Invasive Lethal Cancers.

Authors:  William L Harryman; Kendra D Marr; Ray B Nagle; Anne E Cress
Journal:  Front Cell Dev Biol       Date:  2022-03-01

6.  Transcription factors involved in prostate gland adaptation to androgen deprivation.

Authors:  Rafaela Rosa-Ribeiro; Umar Nishan; Ramon Oliveira Vidal; Guilherme Oliveira Barbosa; Leonardo Oliveira Reis; Carlos Lenz Cesar; Hernandes F Carvalho
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.